Replies to post #2135 on Pozen Inc. (POZN)

[surf1944]

Pozen sues, saying patent infringed
Triangle Business Journal - by Chris Baysden
Date: Tuesday, May 31, 2011, 5:01pm EDT

John Plachetka heads up Pozen.

It looks like Pozen is headed back to the courtroom.

The Chapel Hill pharma said in an SEC document Tuesday that it has filed a lawsuit against Sun Pharma Global FZE for patent infringement in the United States District Court for the Eastern District of Texas.

The lawsuit was prompted by Sun’s previous filing of an Abbreviated New Drug Application with the United States Food and Drug Administration seeking regulatory approval to market a generic version of Treximet, a Pozen migraine drug sold by GlaxoSmithKline (NYSE: GSK).

The announcement comes not long after Pozen (NASDAQ: POZN) announced that it had won a round in the patent litigation that is a common occurrence for pharmaceutical companies.

Treximet provides an important revenue stream for Pozen. In the first quarter, Pozen posted $4.5 million in total revenue – including $4.1 million from Treximet. Pozen is led by CEO John Plachetka.

Read more: Pozen sues, saying patent infringed | Triangle Business Journal